Pacific Biosciences of California, Inc. (PACB)

NASDAQ: PACB · Real-Time Price · USD
1.310
-0.020 (-1.50%)
Mar 25, 2025, 4:00 PM EST - Market closed
-1.50%
Market Cap 390.19M
Revenue (ttm) 154.01M
Net Income (ttm) -309.85M
Shares Out 297.85M
EPS (ttm) -1.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,155,662
Open 1.325
Previous Close 1.330
Day's Range 1.290 - 1.340
52-Week Range 1.160 - 3.890
Beta 1.86
Analysts Buy
Price Target 2.46 (+87.79%)
Earnings Date May 8, 2025

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified ... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Oct 27, 2010
Employees 575
Stock Exchange NASDAQ
Ticker Symbol PACB
Full Company Profile

Financial Performance

In 2024, PACB's revenue was $154.01 million, a decrease of -23.19% compared to the previous year's $200.52 million. Losses were -$309.85 million, 1.02% more than in 2023.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is $2.46, which is an increase of 87.79% from the latest price.

Price Target
$2.46
(87.79% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Natur...

8 days ago - GlobeNewsWire

Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock

Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock

27 days ago - Seeking Alpha

PacBio to Participate in TD Cowen's 45th Annual Health Care Conference

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenti...

4 weeks ago - GlobeNewsWire

PacBio Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee o...

5 weeks ago - GlobeNewsWire

Pacific Biosciences of California, Inc. (PACB) Q4 2024 Earnings Call Transcript

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance and Investor Relation...

5 weeks ago - Seeking Alpha

Trump's Cuts to Medical Research Are Hurting These Stocks

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively.

Other symbols: ILMNTXG
5 weeks ago - Barrons

PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggier...

7 weeks ago - GlobeNewsWire

PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025

MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thur...

7 weeks ago - GlobeNewsWire

PacBio Announces Appointment of Chris Smith to Board of Directors

PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. PacBio to leverage Chris' extensive expertise in diagnostics and l...

7 weeks ago - GlobeNewsWire

PacBio Technology Powers Landmark Multiomic Study Published in Nature Genetics

New sequencing approach resolves the genetic complexity of a rare Mendelian condition New sequencing approach resolves the genetic complexity of a rare Mendelian condition

7 weeks ago - GlobeNewsWire

PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider

MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Se...

2 months ago - GlobeNewsWire

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud Univ...

2 months ago - GlobeNewsWire

PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

Commenced shipment of the Vega ™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers

2 months ago - GlobeNewsWire

PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discover...

2 months ago - GlobeNewsWire

PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenti...

2 months ago - GlobeNewsWire

Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight

Ark Invest CEO Cathie Wood is doubling down on genomics.

3 months ago - Benzinga

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 millio...

4 months ago - Seeking Alpha

PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be particip...

4 months ago - GlobeNewsWire

Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian...

4 months ago - Seeking Alpha

PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a priva...

4 months ago - GlobeNewsWire

PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop

Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing...

4 months ago - GlobeNewsWire

The Schall Law Firm Encourages Investors With Losses To Join An Inquiry Into Pacific Biosciences of California Inc For Fraud

LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci...

5 months ago - Accesswire

The Schall Law Firm Encourages Investors To Join An Inquiry Into Pacific Biosciences of California Inc For Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci...

5 months ago - Accesswire

Pacific Biosciences of California, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci...

5 months ago - Accesswire

The Schall Law Firm Invites Investors To Join An Inquiry Into Pacific Biosciences of California Inc For Fraud

LOS ANGELES, CA / ACCESSWIRE / October 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci...

5 months ago - Accesswire